Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bluejay Diagnostics (BJDX) Change in Account Payables (2022 - 2023)

Bluejay Diagnostics (BJDX) has disclosed Change in Account Payables for 2 consecutive years, with -$254369.0 as the latest value for Q4 2023.

  • Quarterly Change in Account Payables fell 166.95% to -$254369.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$235760.0 through Dec 2023, down 178.88% year-over-year, with the annual reading at $69133.0 for FY2025, 119.96% up from the prior year.
  • Change in Account Payables hit -$254369.0 in Q4 2023 for Bluejay Diagnostics, down from $448199.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $448199.0 in Q3 2023 to a low of -$520728.0 in Q2 2022.